Search

Displaying results 9971 - 9980 of 10000 in total
  1. Drug

    ORM-1153

    go.drugbank.com/drugs/DB33919
    Experimental

    ORM-1153 is a biologic drug. ORM-1153 is under investigation in clinical trial NCT07809906 (Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression).

  2. Drug

    Vopratelimab

    go.drugbank.com/drugs/DB15378
    Investigational

    Vopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors).

  3. Drug

    Rocapuldencel-T

    go.drugbank.com/drugs/DB17588
    Investigational

    Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

  4. Drug

    BMS-830216

    go.drugbank.com/drugs/DB14787
    Investigational

    BMS-830216 is under investigation in clinical trial NCT00909766 (Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects).

  5. Drug

    Cobitolimod

    go.drugbank.com/drugs/DB14819
    Investigational

    Cobitolimod is under investigation in clinical trial NCT03178669 (The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis).

  6. Drug

    Bimiralisib

    go.drugbank.com/drugs/DB14846
    Investigational

    Bimiralisib is under investigation in clinical trial NCT02723877 (PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)).

  7. Drug

    Lucerastat

    go.drugbank.com/drugs/DB14872
    Investigational

    Lucerastat is under investigation in clinical trial NCT03425539 (Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease).

  8. Drug

    Derazantinib

    go.drugbank.com/drugs/DB14889
    Investigational

    Derazantinib is under investigation in clinical trial NCT03230318 (Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma).

  9. Drug

    CHIR-124

    go.drugbank.com/drugs/DB06852
    Experimental

    CHIR-124 is a potent inhibitor of Chk1 that potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.

  10. Drug

    Camidanlumab tesirine

    go.drugbank.com/drugs/DB16411
    Investigational

    Camidanlumab tesirine is under investigation in clinical trial NCT04639024 (ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN).